SEP 07, 2016 01:30 PM PDT

Manipulating the Microbiome to Prevent and Treat Infection

2 2 150

  • Professor of Internal Medicine and Pathology, University of Iowa
      Dr. Diekema is a Professor of Internal Medicine and Pathology at the University of Iowa Carver College of Medicine. After graduating from Vanderbilt University School of Medicine, Dr. Diekema did an internal medicine residency at the University of Virginia, and completed fellowships in infectious diseases, hospital epidemiology and medical microbiology at the University of Iowa, where he also received an MS in Preventive Medicine.
      Dr. Diekema currently serves as director of the Division of Infectious Diseases at the University of Iowa Carver College of Medicine, associate director of the University of Iowa Hospital Clinical Microbiology Laboratory, the associate hospital epidemiologist at University of Iowa Healthcare.
      Dr. Diekema's clinical and research interests include several aspects of healthcare epidemiology, including the epidemiology of invasive fungal infections in hospitalized patients, and the epidemiology of antimicrobial resistance. He has served on national committees that establish standards in clinical microbiology and infection prevention, including the Clinical and Laboratory Standards Institute (CLSI) and the CDC's Healthcare Infection Control Practices Advisory Committee (HICPAC), of which he is currently co-chair. He is also the immediate past-president of the Society for Healthcare Epidemiology of America (SHEA).


    Healthcare associated infections can be a consequence of a microbiome alteration. Increasingly, treatment and prevention strategies focus on manipulating host microbiota, the two most common examples being (1) suppression of certain skin and mucosal microbiota, and (2) preservation or restoration of intestinal microbial communities.

    After this presentation, participants should be able to:  

    (a) discuss the evidence in support of chlorhexidine application to the skin and oropharynx of hospitalized patients to prevent infection
    (b) implement interventions to reduce the likelihood of Clostridium difficile recurrence after host exposure to antimicrobial agents.

    Show Resources
    Loading Comments...